The　intricate　dynamics　of　brain　aging,　especially　the　neurodegenerative　mechanisms　driving　accelerated　(ABA)　and　resilient　brain　aging　(RBA),　are　pivotal　in　neuroscience.　Understanding　the　temporal　dynamics　of　these　phenotypes　is　crucial　for　identifying　vulnerabilities　to　cognitive　decline　and　neurodegenerative　diseases.　Currently,　there　is　a　lack　of　comprehensive　understanding　of　the　temporal　dynamics　and　neuroimaging　biomarkers　linked　to　ABA　and　RBA.　This　study　addressed　this　gap　by　utilizing　a　large-scale　UK　Biobank　(UKB)　cohort,　with　the　aim　to　elucidate　brain　aging　heterogeneity　and　establish　the　foundation　for　targeted　interventions.　Employing　Lasso　regression　on　multimodal　neuroimaging　data,　structural　MRI　(sMRI),　diffusion　MRI　(dMRI),　and　resting-state　functional　MRI　(rsfMRI),　we　predicted　the　brain　age　and　classified　individuals　into　ABA　and　RBA　cohorts.　Our　findings　identified　1949　subjects　(6.2%)　as　representative　of　the　ABA　subpopulation　and　3203　subjects　(10.1%)　as　representative　of　the　RBA　subpopulation.　Additionally,　the　Discriminative　Event-Based　Model　(DEBM)　was　applied　to　estimate　the　sequence　of　biomarker　changes　across　aging　trajectories.　Our　analysis　unveiled　distinct　central　ordering　patterns　between　the　ABA　and　RBA　cohorts,　with　profound　implications　for　understanding　cognitive　decline　and　vulnerability　to　neurodegenerative　disorders.　Specifically,　the　ABA　cohort　exhibited　early　degeneration　in　four　functional　networks　and　two　cognitive　domains,　with　cortical　thinning　initially　observed　in　the　right　hemisphere,　followed　by　the　temporal　lobe.　In　contrast,　the　RBA　cohort　demonstrated　initial　degeneration　in　the　three　functional　networks,　with　cortical　thinning　predominantly　in　the　left　hemisphere　and　white　matter　microstructural　degeneration　occurring　at　more　advanced　stages.　The　detailed　aging　progression　timeline　constructed　through　our　DEBM　analysis　positioned　subjects　according　to　their　estimated　stage　of　aging,　offering　a　nuanced　view　of　the　aging　brain＇s　alterations.　This　study　holds　promise　for　the　development　of　targeted　interventions　aimed　at　mitigating　age-related　cognitive　decline.